GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Other Gross PPE

Roquefort Therapeutics (LSE:ROQ) Other Gross PPE : £0.05 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Other Gross PPE?

Roquefort Therapeutics's Other Gross PPE for the quarter that ended in Dec. 2023 was £0.05 Mil.

Roquefort Therapeutics's quarterly Other Gross PPE increased from Dec. 2022 (£0.00 Mil) to Jun. 2023 (£0.05 Mil) and increased from Jun. 2023 (£0.05 Mil) to Dec. 2023 (£0.05 Mil).

Roquefort Therapeutics's annual Other Gross PPE stayed the same from Dec. 2021 (£0.00 Mil) to Dec. 2022 (£0.00 Mil) but then increased from Dec. 2022 (£0.00 Mil) to Dec. 2023 (£0.05 Mil).


Roquefort Therapeutics Other Gross PPE Historical Data

The historical data trend for Roquefort Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Other Gross PPE Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Other Gross PPE
- - 0.05

Roquefort Therapeutics Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23
Other Gross PPE - - - 0.05 0.05

Roquefort Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Roquefort Therapeutics (LSE:ROQ) Business Description

Traded in Other Exchanges
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines